Telaprevir for previously untreated chronic hepatitis C virus infection
Abstract
Telaprevir with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in t …
Keywords
hepatitis c
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
RNA
humans
pubmed abstract
nih
national institutes of health
national library of medicine
logistic models
research support
non-u.s. gov't
adult
female
male
aged
middle aged
young adult
Clinical Trial
Phase III
Randomized Controlled Trial
Double-Blind Method
Multicenter Study
DNA
Sequence Analysis
viral / blood
drug therapy
combination
antiviral agents / therapeutic use*
recombinant proteins
viral load
hepacivirus / isolation & purification
chronic / virology
antiviral agents / adverse effects
pmid:21696307
doi:10.1056/nejmoa1012912
ira m jacobson
john g mchutchison
advance study team
hepacivirus / genetics*
chronic / drug therapy*
interferon alpha-2
interferon-alpha / adverse effects
interferon-alpha / therapeutic use*
oligopeptides / adverse effects
oligopeptides / therapeutic use*
polyethylene glycols / adverse effects
polyethylene glycols / therapeutic use*
serine proteinase inhibitors / adverse effects
serine proteinase inhibitors / therapeutic use*
Access
Citation
ID:
114486
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
114486
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet